Evidence for genetic factors in the development and progression of IgA nephropathy

被引:139
作者
Hsu, SIH
Ramirez, SB
Winn, MP
Bonventre, JV
Owen, WF
机构
[1] Natl Univ Singapore, Fac Med, Dept Med, Singapore 117548, Singapore
[2] Natl Univ Singapore, Fac Med, Dept Pediat, Singapore 117548, Singapore
[3] Natl Kidney Fdn Singapore, Div Res, Singapore, Singapore
[4] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA
[5] Harvard Univ, Sch Med, Boston, MA USA
[6] Duke Univ, Med Ctr, Duke Inst Renal Outcomes Res & Hlth Policy, Durham, NC USA
[7] Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC USA
[8] Duke Univ, Med Ctr, Duke Ctr Human Genet, Durham, NC USA
[9] Massachusetts Gen Hosp, Renal Unit, Boston, MA 02114 USA
关键词
heredity; IgAN; familial nephropathy; glomerulonephritis; chronic renal failure; hematuria;
D O I
10.1046/j.1523-1755.2000.00032.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background IgA nephropathy (IgAN) is the most common glomerulonephritis in the world among patients undergoing renal biopsy. Once considered a relatively benign condition, longitudinal follow-up studies have revealed that in fact 9 to 50% of patients progress to end-stage renal disease within 20 years of disease onset. In the three decades since its first description by Jean Berger and Nicole Hinglais, clinical, epidemiologic, and immunologic studies of the pathogenesis of primary (idiopathic) mesangial glomerulonephritis with predominant IgA deposits have characterized the features of IgAN as a distinct glomerular disease entity. However, the basic molecular mechanism(s) underlying abnormal IgA deposition in the mesangium with ensuing extracellular matrix expansion and mesangial cell proliferation remains poorly understood. The task of elucidating the molecular basis of IgAN is made especially challenging by the fact that both environmental and genetic components likely contribute to the development and progression of IgAN. Methods and Results. We review here the evidence for genetic factors in the development and progression of IgAN, including a reappraisal of earlier conflicting results from small immunogenetic case-control studies, the evidence for racial differences in the prevalence of IgAN, a detailed summary of all reported occurrences of familial IgAN worldwide, and an exhaustive review of new insights gained through the study of two murine models of hereditary IgAN: the ddY and the uteroglobin-deficient mouse. Conclusions. With the development of powerful molecular genetic approaches to the study of both Mendelian and complex human genetic diseases, and the successful efforts of investigators to identify and clinically characterize large IgAN multiplex families, we propose that genetic analysis of familial IgAN is the most promising approach to the identification of IgAN disease/susceptibility genes. Alternatively, if the case-control study design is employed to identify associations between particular candidate genes or markers and the development of IgAN, spurious associations caused by the effects of population stratification should be ruled out by confirming the findings using powerful and sensitive family-based methodologies such as the transmission/dysequilibrium test (TDT).
引用
收藏
页码:1818 / 1835
页数:18
相关论文
共 146 条
  • [1] Allen AC, 1999, J AM SOC NEPHROL, V10, P1763
  • [2] Andreucci VE, 1998, J NEPHROL, V11, P105
  • [3] Association of the angiotensin I converting enzyme gene deletion polymorphism with early onset of ESRF in PKD1 adult polycystic kidney disease
    Baboolal, K
    Ravine, D
    Daniels, J
    Williams, N
    Holmans, P
    Coles, GA
    Williams, JD
    [J]. KIDNEY INTERNATIONAL, 1997, 52 (03) : 607 - 613
  • [4] BERGER J, 1969, TRANSPL P, V1, P939
  • [5] BERGER J, 1968, J UROL NEPHROL, V74, P694
  • [6] BERTHOUX FC, 1978, NEW ENGL J MED, V298, P1034
  • [7] BERTHOUX P, 1995, CONTRIB NEPHROL, V111, P24
  • [8] BEUKHOF JR, 1984, CLIN NEPHROL, V22, P195
  • [9] BEUKHOF JR, 1987, SEMIN NEPHROL, V7, P367
  • [10] Racial difference in the relationship of an angiotensin I-converting enzyme gene polymorphism to serum angiotensin I-converting enzyme activity
    Bloem, LJ
    Manatunga, AK
    Pratt, JH
    [J]. HYPERTENSION, 1996, 27 (01) : 62 - 66